EMA ERA Decision Tree & Navigator
Interactive decision-support tool for navigating Phase I and PBT/vPvB ERA pathways.
Scientific risk assessment and regulatory documentation across pharmaceuticals, medical devices and cosmetics — from environmental and occupational exposure to impurities, biocompatibility and product safety.
Focused scientific assessments and clear documentation for pharmaceutical, medical-device, cosmetic and related product-safety requirements.
Phase I environmental exposure screening, Phase II fate and ecotoxicity assessment where required, PEC/PNEC characterisation and relevant PBT/vPvB review.
PDEHealth-based exposure limit derivation supported by hazard review, critical-effect selection, point-of-departure rationale and justified adjustment factors.
OELOccupational exposure limit derivation, exposure banding and industrial-hygiene context to support workplace exposure and control decisions.
ICH M7Pharmaceutical impurity and nitrosamine risk assessment, ICH M7 evaluation and evidence-led QSAR / OECD Toolbox-based support.
CTDNon-clinical summaries, risk assessments and CTD/eCTD documentation, including applicable Modules 2.4, 2.5, 2.6, 2.7 and 4.
ISOBiocompatibility and extractables/leachables support under relevant ISO frameworks, alongside cosmetic safety assessments and CPSR preparation.
Substance, product, route, intended market and submission context are established before scope is fixed.
Available regulatory, literature, pharmacological, toxicological and environmental evidence is evaluated for relevance and reliability.
The agreed assessment is translated into structured scientific documentation with clear rationale and traceable scope.
Explore regulatory concepts before requesting a project-specific assessment. These background pages link to official guidance and explain ToxWriter service areas.
Interactive decision-support tool for navigating Phase I and PBT/vPvB ERA pathways.
How the environmental assessment progresses from environmental exposure screening to further fate, effects and risk characterisation.
How the current EMA framework relates to UK ERA submissions and UK prevalence considerations.
Why population fraction and treatment context can affect the Phase I environmental exposure estimate.
How a health-based exposure limit is derived from pharmacology, toxicology, a point of departure and adjustment factors.
How workplace exposure limits and exposure bands fit into occupational risk management.
A practical comparison of three distinct regulatory and occupational exposure concepts.
How ICH M7 and Q3A/Q3B frameworks inform impurity identification, qualification and control.
EU and Great Britain CPSR preparation, cosmetic safety assessment and the Product Information File.
We will review the requested scope and confirm the appropriate assessment pathway, information needs and next step.